ArticleJournal for immunotherapy of cancer2026

Phase 1b study of ABBV-368, tilsotolimod, budigalimab, and nab-paclitaxel in patients with recurrent/metastatic head and neck squamous cell carcinoma.

Amaury Daste et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.